PRC 4016 (Icosabutate) - A Phase I, Single-Blind, Placebo Controlled, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects
Latest Information Update: 16 Oct 2020
At a glance
- Drugs Icosabutate (Primary)
- Indications Dyslipidaemias; Hypertriglyceridaemia; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pronova BioPharma
- 29 Aug 2020 Results presented at The International Liver Congress 2020
- 24 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Feb 2015 New trial record